Searchable abstracts of presentations at key conferences on calcified tissues

ba0004p70 | (1) | ICCBH2015

Ultrasonographic assessment of the skeletal development of the proximal tibia epiphysis, the proximal femur and the distal femur epiphysis in premature and mature newborns

Windschall Daniel , Pommerenke Michael , Rimsl Theresa , Haase Roland

Backround: Usually, skeletal development and bone age in children are still examined by x-ray. In obstetrics the use of fetal ultrasonography (US) of the distal femoral epiphyseal (DFE) and proximal tibial epiphyseal (PTE) ossification centers helps to identify intrauterine growth retardation. And US has been shown to be an excellent tool to assess the mineralization of bones. First ultrasound studies were following the mineralization of bones in young infants.<p class="ab...

ba0003pp192 | Genetics | ECTS2014

Genetic determinants of bone mineral density loss in aromatase inhibitors treatment in the B-ABLE Cohort

Rodriguez-Sanz Maria , Garcia-Giralt Natalia , Torres-del Pliego Elisa , Prieto-Alhambra Daniel , Servitja Sonia , Balcells Susana , Mellibovsky Leonardo , Grinberg Daniel , Tusquets Ignasi , Diez-Perez Adolfo , Nogues Xavier

Bone density (BMD) loss is a consequence of aromatase inhibitors (AI) treatment of breast cancer. B-ABLE cohort includes 391 postmenopausal women with early breast cancer starting AI therapy. Participants experienced a 1.98% (95% CI 1.54–2.42% P<0.0001) bone loss at lumbar spine (LS) and 1.24% (95% CI 0.81–1.67% P<0.0001) bone loss at femoral neck (FN) after 1 year on AI therapy and a 3.51% (95% CI 3.00–4.03% P<0.0001) bone...

ba0001oc2.5 | Bone quality and fracture repair - animal models | ECTS2013

Glucagon-like peptide 1 receptor is required for optimal bone strength and quality

Mieczkowska Aleksandra , Irwin Nigel , Flatt Peter R , Chappard Daniel , Mabilleau Guillaume

Objectives: Glucagon-like peptide 1 is secreted by intestinal L-cells into the blood supply in response to nutrients in the intestine. Although osteoblasts express the GLP-1 receptor (GLP-1R), the main action of the GLP-1/GLP-1R pathway in bone physiology and bone quality is unknown. The aim of the present study was to investigate bone strength and quality in a mouse model of GLP-1R deficiency.Materials/methods: Eight 16 weeks-old GLP-1R knock-out male m...

ba0001pp39 | Bone biomechanics and quality | ECTS2013

Glucose-dependent insulinotropic polypeptide receptor deletion results in a reduced bone strength and quality

Mieczkowska Aleksandra , Irwin Nigel , Flatt Peter R , Chappard Daniel , Mabilleau Guillaume

Objectives: Glucose-dependent insulinotropic polypeptide (GIP) is secreted by intestinal K-cells into the blood supply in response to nutrient ingestion and absorption. Although osteoblasts and osteoclasts express the GIP receptor (GIPR), the main action of the GIP/GIPR pathway in bone physiology and bone quality is unknown. The aim of the present study was to investigate bone quality in a mouse model of GIPR deficiency.Materials/methods: Eleven 16 weeks...

ba0001pp62 | Bone development/growth and fracture repair | ECTS2013

Intermittent administration of parathyroid hormone (1–34) may induce the formation of cementum and bone: a histological study in rats

Vasconcelos Daniel , Marques Marcelo , Barros Silvana , Vasconcelos Any Carolina , Benatti Bruno , Novaes Pedro

The aim of this study was to evaluate the effect of anabolic PTH on periodontal repair and mandibular bone defect in rats. Fenestration defects were created unilaterally of lower first molars in Wistar rats (n=32), and both periodontal ligament and cementum were removed. Animals were treated 3 times a week and then assigned to four groups (n=8): i) C14 – placebo administration for 14 days; ii) P14 – PTH administration for 14 days; iii) C21 – pl...

ba0001pp70 | Bone development/growth and fracture repair | ECTS2013

A casein-based diet leads to a better bone status than a soy protein-based diet during moderate protein restriction in growing mice

Rouy Emilien , Laroche Norbert , Blachier Francois , Tome Daniel , Vico Laurence , Blais Anne

This study aims at determining if casein would lead to a better bone status than soy in the context of a moderate protein restriction (6% of total energy intake) in growing mice.Ten-week-old female Balb/C mice were divided in four groups of 15 animals. Two groups received 6% of their energy intake as protein, one as casein and the other as soy protein. The third group was a normal-protein control receiving 20% soy protein. The last group (positive contro...

ba0001pp143 | Cancer and bone: basic, translational and clinical | ECTS2013

Bone remodelling in patients with an IgM monoclonal gammopathy (Waldenstrom disease – MGUS)

Chappard Daniel , Bouvard Beatrice , Royer Mathieu , Hoppe Emmanuel , Legrand Erick , Ifrah Norbert , Audran Maurice

An IgM monoclonal gammopathy (MGUS) is often the first sign of a lymphomonocytic B-lymphoma (Waldenström macroglobulinemia-WD). Osteolytic lesions can occur in B cell malignancies (WD, hairy cell leukemia, LLC\..) but are less frequent than in myeloma. In addition, bone remodeling in WD is poorly understood. However, an osteoporosis is often observed in MGUS patients. We studied a series of bone biopsies performed in patients with an IgM gammopathy by histomorphometry, mi...

ba0001pp284 | Muscle, physical activity and bone | ECTS2013

Raising CK: what it means according to different clinical landscape?

Juan Jose Scali , Visentini Susana , Berruezo Ramiro , Sevilla Daniel , Pacheco Gonzalo , Garcia Rodrigo

Introduction: The creatine kinase (CK) is a dimeric enzyme, involved in energetical metabolism. It is present in many tissues, but higher concentration in skeletal and cardiac muscle.Therefore, conditions that involve muscle tissue may increase this serum enzyme. Such enzyme elevation is usually observed in inflammatory myopathies and others autoimmune diseases.Sometimes some elevation in CK is not fully understood out off these co...

ba0001pp403 | Osteoporosis: treatment | ECTS2013

Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis

Makras Polyzois , Polyzos Stergios , Papatheodorou Athanasios , Kokkoris Panagiotis , Chatzifotiadis Daniel , Anastasilakis Athanasios

Purpose: Denosumab is a new potent antiresorptive treatment of osteoporosis that can potentially induce a compensatory increase of parathyroid hormone (PTH) levels. We aimed to evaluate the alteration of PTH 1 and 6 months after denosumab’s administration (60 mg) with different regimens of calcium and vitamin D (Ca/D) supplementation, as well as the association of PTH with serum Ca and bone markers.Methods: This was a prospective, multicenter, study...

ba0001pp488 | Other diseases of bone and mineral metabolism | ECTS2013

Circulating RANKL is not a reliable biomarker for bone loss in primary hyperparathyroidism

Grigorie Daniel , Sucaliuc Alina , Neacsu Elena , Militaru Roxana , Diaconescu Alina , Ivan Mirela

Introduction: The aim was to examine serum levels of RANKL, OPG and TNF-α before and after curative surgery (PTX) in patients with primary hyperparathyroidism, and their relationship to bone turnover and bone loss.Patients and methods: A 46 patients with rather severe primary hyperparathyroidism (mean PTH=196 pg/ml, mean total Ca=11.4 mg/dl, spine osteoporosis in 50%, hip osteoporosis in a third) mean age of 63.3±12.3 years, 41 women/five males...